Joshua A Fein
Overview
Explore the profile of Joshua A Fein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fein J, McAuliffe A, Fischer K, Brady O, Devlin S, Willumsen S, et al.
Leuk Lymphoma
. 2024 Dec;
:1-8.
PMID: 39641218
Access to allogeneic and autologous hematopoietic stem cell transplantation (SCT) remains inadequate despite its curative potential across hematologic malignancies. In 2015, Hartford HealthCare (HHC) and the Memorial Sloan Kettering Cancer...
2.
Boardman A, Gutgarts V, Flynn J, Devlin S, Goldman A, Tomas A, et al.
Haematologica
. 2024 Nov;
110(3):651-664.
PMID: 39568416
Chimeric antigen receptor (CAR) T cells targeting CD19 induce durable remissions in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), but many patients experience treatment-related toxicity. Cytokine release syndrome and...
3.
Pophali P, Fein J, Ahn K, Allbee-Johnson M, Ahmed N, Awan F, et al.
Blood Adv
. 2024 Jul;
8(20):5290-5296.
PMID: 38985302
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare histologic variant of LBCL. Limited data regarding CD19-directed chimeric antigen receptor T-cell (CART) therapy in relapsed/refractory (R/R) THRLBCL suggest poor efficacy. We...
4.
Saldarriaga M, Pan D, Unkenholz C, Mouhieddine T, Velez-Hernandez J, Engles K, et al.
Blood Adv
. 2024 May;
8(15):3859-3869.
PMID: 38776397
B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T cells (CAR-Ts) used in multiple myeloma (MM) are rapidly becoming a mainstay in the treatment of relapsed/refractory (R/R) disease, and CAR-T expansion...
5.
Shouval R, Goldman A, Flynn J, El-Moghraby A, Rehman M, Devlin S, et al.
Br J Haematol
. 2024 May;
205(3):978-989.
PMID: 38735683
Recent reports have raised concerns about the association of chimeric antigen receptor T cell (CAR-T) with non-negligible cardiotoxicity, particularly atrial arrhythmias. First, we conducted a pharmacovigilance study to assess the...
6.
Donor genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight
Schetelig J, Baldauf H, Heidenreich F, Hoogenboom J, Spellman S, Kulagin A, et al.
Front Immunol
. 2024 Apr;
15:1350470.
PMID: 38629074
Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor's Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important information in this regard....
7.
8.
Youngster I, Eshel A, Geva M, Danylesko I, Henig I, Zuckerman T, et al.
Bone Marrow Transplant
. 2024 Jan;
59(3):409-416.
PMID: 38212672
Acute graft-versus-host disease (aGvHD) is a serious complication of allogeneic hematopoietic stem-cell transplantation with limited treatment options. The gut microbiome plays a critical role in aGvHD pathogenesis. Fecal microbiota transplantation...
9.
Shouval R, Fein J
Hematology Am Soc Hematol Educ Program
. 2023 Dec;
2023(1):715-722.
PMID: 38066892
Allogeneic hematopoietic cell transplantation (alloHCT) requires the comprehensive evaluation of patients across multiple dimensions. Among the factors considered, comorbidities hold great significance in the pretransplant assessment. As many as 40%...
10.
Fein J, Shouval R, Krieger E, Spellman S, Wang T, Baldauf H, et al.
Blood Adv
. 2023 Dec;
8(3):581-590.
PMID: 38052043
In acute myeloid leukemia (AML), donor natural killer cell killer immunoglobulin-like receptors (KIR) and recipient HLA interactions may contribute to the graft-versus-leukemia effect of allogeneic hematopoietic cell transplantation (HCT). Analyses...